Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


Revenue 2017


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

Pfizer decides against long-discussed break-up

Pfizer decides against long-discussed break-up Medivation adds another fast-growing prostate cancer treatment Xtandi (enzalutamide), which posted $1.9bn in sales last year.

Deal Watch August 2016

Deal Watch August 2016 35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.

Pfizer rides out Sanofi and confirms $14bn Medivation takeover

Pfizer rides out Sanofi and confirms $14bn Medivation takeover Success of cancer specialist’s drug Xtandi followed by work on other cancer drugs. ... There is plenty of room for further growth of Xtandi, according to analysts.

Astellas promotes John Demaree

Astellas promotes John Demaree Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).

Medivation softens on Sanofi takeover and opens its books

Medivation softens on Sanofi takeover and opens its books The main prize at present for Sanofi is the fast-growing prostate cancer drug Xtandi (enzalutamide), which made $1.9bn in sales last year, and which Medivation is attempting to move

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs


Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...